H. Ballentine Carter

Author

Johns Hopkins University

Also Known As

H Ballentine Carter, H. BALLENTINE CARTER, H. Ballentine Carter

Publications

941

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Johns Hopkins Hospital New York University Dianon (United States)Gannon University

About

H. Ballentine Carter is an author at Johns Hopkins University specializing in urology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	67
2	Public Health	3	3	65
3	Arts	1	1	23
4	Communication	1	1	23
5	Epidemiology	1	1	10

H. Ballentine Carter

Publications

928

Citations

H-Index

Page 1

	Year	Citations
Prostate Specific Antigen in the Staging of Localized Prostate Cancer: Influence of Tumor Differentiation, Tumor Volume and Benign Hyperplasia Alan W. Partin, H. Ballentine Carter, Daniel W. Chan, The Journal of Urology	1990	622
Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer Jay D. Pearson, Albert A. Luderer, E. Jeffrey Metter, Urology	1996	67
THE SIGNIFICANCE OF PRIOR BENIGN NEEDLE BIOPSIES IN MEN SUBSEQUENTLY DIAGNOSED WITH PROSTATE CANCER Jonathan I. Epstein, Patrick C. Walsh, George Akingba, The Journal of Urology	1999	45
The Relationship of Prostate Specific Antigen Levels and Residual Tumor Volume in Stage a Prostate Cancer H. Ballentine Carter, Alan W. Partin, Jonathan I. Epstein, The Journal of Urology	1990	42
Multicenter comparison of the diagnostic performance of free prostate-specific antigen Robert Thiel, Joseph E. Oesterling, Kirk J. Wojno, Urology	1996	35
Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions Stacy Loeb, Qinlian Zhou, Uwe Siebert, European Urology UrologyCancer DetectionCancer ScreeningLocalized Prostate CancerMedicine	2017	32
Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer R. Thiel, Jay D. Pearson, Jonathan I. Epstein, Urology	1997	27
Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages Kevin S. Ross, Harry A. Guess, H. Ballentine Carter Urology UrologyCancer ScreeningMedicineCancer ManagementDifferent Ages	2005	25
Informational needs during active surveillance for prostate cancer: A qualitative study Stacy Loeb, Caitlin Curnyn, Angela Fagerlin, Patient Education and Counseling Participatory SurveillanceHealth DataMedical PrivacyHealth CommunicationInformational Needs	2017	23
Heterogeneity in active surveillance protocols worldwide. Stacy Loeb, H. Ballentine Carter, Mark D. Schwartz, PubMed Information SecurityInformation ForensicsGynecology OncologyUrogenital RadiologyClinical Epidemiology	2014	10

Page 1